Meeting
2013 ASCO Annual Meeting
Updated use of first-line chemotherapy for advanced pancreatic cancer: Folfirinox versus gemcitabine.
Authors
Thomas H. Cartwright
Ocala Oncology, The US Oncology Network, Ocala, FL
Thomas H. Cartwright , Aimee Ginsburg Arlen , Lalan S. Wilfong , Robyn K. Harrell , J. Russell Hoverman , Roy A. Beveridge
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research
Track
Health Services Research
Sub Track
Outcomes and Quality of Care
Citation
J Clin Oncol 31, 2013 (suppl; abstr 6607)
DOI
10.1200/jco.2013.31.15_suppl.6607
Abstract #
6607
Poster Bd #
19G
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine-based therapy.
First Author: Thomas H. Cartwright
Poster
2018 ASCO Quality Care Symposium
Treatment patterns, toxicity, and outcomes of elderly patients with advanced pancreatic cancer receiving first-line chemotherapy.
First Author: Robert Kudlovich
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy of the third-line chemotherapy in patients with advanced pancreatic cancer.
First Author: Bomi Kim
Poster
2016 Gastrointestinal Cancers Symposium
Early tumor shrinkage as a predictor of favorable outcomes in patients (pts) with advanced pancreatic cancer treated with FOLFIRINOX.
First Author: Yasuhiro Kaga